Brief: US FDA Study May Proceed Letter For Clarity's Cu-64 Sar-Bispsma Trial In Prostate Cancer
07/02/2022 14:17
Feb 7 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* US FDA STUDY MAY PROCEED LETTER FOR CLARITY'S CU-64
SAR-BISPSMA
TRIAL IN PROSTATE CANCER
* CLARITY PHARMACEUTICALS - HAS RECEIVED A CONFIRMATION FROM
US
FDA THAT DIAGNOSTIC (64)CU SAR-BISPSMA TRIAL (COBRA) MAY PROCEED
Source text for Eikon: ID:nPn8WLYCwa
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial